bioRxivGenomicsPreprint
Variable latency between the founder genetic event and rhabdoid tumor expansion
Mònica Sánchez-GuixéiD, Alex Cebria‐XartiD, Naomi FabreiD, Carlos J. Rodríguez-HernándeziD, Morena Pinheiro-SantiniD, Cinzia Emilia LavarinoiD, Jarno DrostiD, Ruben van BoxteliD, Núria López-BigasiD, Alexandra AvgustinovaiD, Abel González-PéreziD
- Citations
- 0
Abstract
Rhabdoid tumors are very aggressive rare pediatric cancers with poor survival affecting very young children. They are characterized by the bi-allelic loss of SMARCB1 or SMARCA4, which is suspected to occur prenatally. However, their genomic evolution is not well understood. Here we assembled the largest cohort of whole-genome sequenced rhabdoid tumors to date, comprising 97 tumors from 88 children. We discovered that, in 42% of cases, the bi-allelic inactivation of the driver gene occurred via a Copy Number Neutral-Loss of Heterozygosity (CN-LOH). We exploited these CN-LOH events and the steady accumulation of age-related mutations in the tumor genomes to estimate the age of donors at the time of occurrence of the driver event and at the time of emergence of the clonal expansion. Across all cases with CN-LOH, the loss of the driver gene occurred very early during prenatal development. However, the clonal expansion that ultimately gave rise to the tumor occurred at different times during infancy, even several years after the acquisition of the founder event. These results indicate that probably other factors, besides the genetic driver event, are required to promote rhabdoid tumorigenesis.
- organism: human
- assay: whole-genome sequencing
- research focus: variant calling
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Diverse Mechanisms of SMARCB1 Inactivation and Genome Maintenance Defects in Ultra-Rare Malignant Rhabdoid Tumors
Elizabeth Rasmussen, Elena Mironova, … Raushan T. Kurmasheva·bioRxiv·Mar 2, 2026
- SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth
N. Q. Liu, I. Paassen, … J. Drost·bioRxiv·Nov 21, 2022
- Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors
A. Henssen, R. Koche, … A. Kentsis·bioRxiv·Feb 23, 2017
- miR-16 suppresses growth of rhabdoid tumor cells
Emily Kunce Stroup, Yunku Yeu, … Kenneth S. Chen·bioRxiv·Nov 22, 2017
- Origins and timing of emerging lesions in advanced renal cell carcinoma
A. Wallace, S. Porten, … M. Meng·bioRxiv·Jun 27, 2021
- Direct therapeutic targeting of SWI/SNF induces epigenetic reprogramming and durable tumor regression in rhabdoid tumor
M. H. Chasse, B. K. Johnson, … P. J. Grohar·bioRxiv·Dec 3, 2019